Daniel A Rothenberg, PhD

Proteomics/Immunopeptidomics for @BioNTech_Group. Alum of @MITdeptofBE and @UTBiomedical. Tweets are my own opinions. Random sports ranting at @drothenberg0121

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

Does anyone know how to easily transfer the accounts I follow on here onto Bluesky/Mastadon/Threads/etc? I'm getting off this hellscape of a site but don't want to lose out on all the good science discussions

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

@tomlau Thank you for tipping me off to this! Made my morning

[ACIR @ACIR_org]

New insights into overcoming immune deserts in tumors  @tronmainz  @BioNTech_Group. Read our digest here 👉 https://t.co/1TZZdDhwyb

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

Very excited to be able to contribute to this project :)

[Cell @CellCellPress]

Now online! A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease https://t.co/5KfD33VtKI

[BioNTech SE @BioNTech_Group]

We are pleased to announce our strategic partnership with @CEPIvaccines to advance the development of our #mRNA based BNT166 #vaccine program for the prevention of mpox. https://t.co/4HS2KZvjpO

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

@SantiCorreaPhD @rltruby I know some of these people! Congrats!

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

@camtflower @chrashwood @xienyuChua Will need a tetrabrid for that 😆

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

😅

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

@CMichaelRose @JohnRYatesIII Go stros!

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

@djscristo Curious to hear your interpretation

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

It's so beautiful 😍🥹🤓

[Charlie Dulberger @chaaawie]

Happy to share some of the innovative work at @BioNTech_Group. It's been amazing to have an insider perspective on the development of T cell-directed vaccine tech -- always thinking about ways to manipulate the T cell synapse to modulate immunity!
https://t.co/nS5Z6g07Vu

[Eric Topol @EricTopol]

A T-cell directed vaccine against Covid, with non-spike, conserved antigens (e.g. nucleocapsid, ORF1ab), effective in experimental models for preventing disease, has gone into clinical trials https://t.co/Iahj9pTCzI
https://t.co/JbQYGGjd8c @CellCellPress

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

I’m so excited to share our journey developing a T-cell-directed mRNA vaccine for SARS-CoV-2 that can complement existing Spike-based vaccines. I’m incredibly grateful to be able to work with such a talented team to advance this technology to the clinic.

[Cell @CellCellPress]

Now online! The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection https://t.co/YhEi6l4gKA

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

@brybry0814 Would love that! Let me see what we can do

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

Come work with us!!

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

@tomlau @SAMyers_lab @lkpino @ProteomicsNews @mjmaccoss @BroadProteomics Speaking of which…

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

@tomlau @SAMyers_lab @lkpino @ProteomicsNews @mjmaccoss @BroadProteomics I’m truly honored to be included in the “brain trust”

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

@CD_McGann @mjmaccoss Congrats man, what an incredible honor and a great way to celebrate her legacy

[Daniel A Rothenberg, PhD @AspAlaArgPhD]

@abhipataskar42 @BioNTech_Group Excited to have you aboard!!